Eldisine
Categoria
Eldisine Nombres de marca, Eldisine Analogos
Eldisine Marca los nombres de mezcla
Eldisine Formula quimica
C43H55N5O7
Eldisine RX enlace
http://www.rxlist.com/cgi/generic2/vinor_cp.htm
Eldisine FDA hoja
Eldisine MSDS (hoja de seguridad de materiales)
Eldisine Sintesis de referencia
GJ Cullinan, K. Gerzon, Alemania. pat. 2.415.980 (1974 a Lilly)
Eldisine Peso molecular
753.926 g/mol
Eldisine Punto de fusion
230-232 oC
Eldisine H2O Solubilidad
No hay información disponible
Eldisine Estado
Solid
Eldisine LogP
4.002
Eldisine Formas de dosificacion
Solución de mensajería instantánea, Polvo para solución
Eldisine Indicacion
Para el tratamiento agudo de leucemia, linfoma maligno, enfermedad de Hodgkin, erythraemia aguda y panmielosis aguda
Eldisine Farmacologia
Vindesina está indicado para el tratamiento de la leucemia linfocítica aguda de la infancia que es resistente a la vincristina y de pulmón de células no avena cancer.Vindesine causas de la detención de las células en la mitosis en metafase. Es tres veces más potente que la vincristina y casi 10 veces más potente que la vinblastina en la causa de arresto mitótico en estudios in vitro a dosis diseñado para arresto de 10 a 15% de las células mitosis. Vindesina y la vincristina son aproximadamente equipotentes a niveles de dosis que el arresto de 40 a 50% de las células en la mitosis. A diferencia de vinblastina, vindesina produce células postmetaphase muy pocos. Vindesina ha demostrado actividad en pacientes que han sufrido una recaída durante el tratamiento con fármacos múltiples de tratamiento que incluía vincristina.
Eldisine Absorcion
No hay información disponible
Eldisine Toxicidad
No hay información disponible
Eldisine Informacion de Pacientes
Patient Information:
The treatmewnt with Vindesine can cause hair, but it is usually reversible. It may also cause
loss of sensation or tingling in hands or feet, fever, chill, sore throat, constipation, black
stool, bruising or bleeding.
Patients should be informed that the major acute toxicities of Vindesine are related to bone
marrow toxicity, specifically granulocytopenia with increased susceptibility to infection.
They should be advised to report fever or chills immediately. Women of childbearing potential
should be advised to avoid becoming pregnant during treatment. Patients should be advised to
contact their physician if they experience increased shortness of breath, cough, or other new
pulmonary symptoms, or if they experience symptoms of abdominal pain or constipation.
The treatmewnt with Vindesine can cause hair, but it is usually reversible. It may also cause
loss of sensation or tingling in hands or feet, fever, chill, sore throat, constipation, black
stool, bruising or bleeding.
Patients should be informed that the major acute toxicities of Vindesine are related to bone
marrow toxicity, specifically granulocytopenia with increased susceptibility to infection.
They should be advised to report fever or chills immediately. Women of childbearing potential
should be advised to avoid becoming pregnant during treatment. Patients should be advised to
contact their physician if they experience increased shortness of breath, cough, or other new
pulmonary symptoms, or if they experience symptoms of abdominal pain or constipation.
Eldisine Organismos afectados
Humanos y otros mamíferos
